We then sought to assess in greater detail the immunological effects of targeting TGF-β in our tumor models treated with the combination of immunogenic chemotherapy consisting of CDDP-Eri and anti–PD-L1 therapy. This evidence concerns the gene TGFB1 and neoplasm.